Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure

SAN FRANCISCO, Dec. 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced preliminary data from its recently completed multi-center, open-label, ascending-dose Phase 1b clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients with heart failure. Results of this study showed:

  • CD-NP was well tolerated at doses of up to 20 ng/kg/min
  • Blood pressure effects were dose dependent and well characterized
  • CD-NP demonstrated diuretic effects comparable to furosemide
  • CD-NP produced statistically significant changes on biomarkers consistent with enhanced renal function

These positive results are supportive of further study to fully validate proof-of-concept of CD-NP in a Phase 2b clinical trial planned to begin in 2009.

About the Study

The objectives of the Phase 1b study were to establish the maximum tolerated dose (MTD) and to assess the pharmacodynamic effects of CD-NP on blood pressure and renal function in stable heart failure patients. Patients with NYHA Class II or Class III heart failure, ejection fraction <40% and current signs of fluid overload were included in the study. In this dose escalation trial, four cohorts were administered a single 24-hour infusion of CD-NP at a dose of either 3 (n=6), 10 (n=6), 20(n=6) or 30 ng/kg/min (n=2). During the infusion of CD-NP, furosemide and vasoactive therapies were withheld.

Effects on Blood Pressure

The effects on blood pressure were dose-dependent. During a 24-hour infusion of CD-NP at doses of 3, 10 and 20 ng/kg/min, mean reductions in Mean Arterial Pressure were 2.2, 8.9 and 13.2 mmHg respectively.

CD-NP was well-tolerated at dos

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
(Date:4/23/2015)... 2015 Ralco announced today that it ... (ABN) for the exclusive worldwide rights to sell and ... is a new in-line milk system that increases the ... to move supplementation milk cups within a farrowing facility ... technology lets producers get Birthrightâ„¢ milk to the right ...
(Date:4/23/2015)... 2015 Six startups from Russia ... 4-17 as part of the U.S.-Russia Innovation Corridor ... of biotechnology startups to participate in the program ... and the University of Maryland (UMD) signed a ... respective universities in the biomedical industry in 2013. ...
(Date:4/23/2015)... , April 23, 2015  Veracyte, Inc. (NASDAQ: ... a definitive agreement to sell approximately $40 million of ... agreement, the investors will purchase an aggregate of 4,907,975 ... $8.15 per share, the closing stock price on April ... and existing investors, including Broadfin Capital, Camber Capital, Deerfield, ...
(Date:4/23/2015)... April 23, 2015  Propanc Health Group Corporation ... focuses on the development of cancer treatments for ... lead product includes PRP, a patented formulation consisting ... as well as the enzyme amylase designed to ... a combination of anti-cancer agents working in combination ...
Breaking Biology Technology:Ralco Acquires License to Birthrightâ„¢ Moveable Milk Cup 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... ... working in continuous flow chemistry processing, will deal with the application of the ReactIR flow ... of over 670 publications has been recognized with several prestigious prizes and awards, including most ... ...
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Healthcare Conference on Wednesday, November 11, at 9:30 a.m. ... may access a live webcast of the presentation on ... It is recommended that listeners log on 15 minutes ...
... 4 Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ... and webcast discussing the Company,s 2009 third quarter results on ... Flavin, Ph.D., Chairman & Chief Executive Officer, as well as ... update on the Company. A press release reporting the 2009 ...
Cached Biology Technology:Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3Advanced Life Sciences to Host 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Va. Marc Edwards and Simoni Triantafyllidou of Virginia ... Best of Children,s National Medical Center, published a 2009 ... that demonstrated a major increase in childhood lead poisoning ... The research contradicted years of government assertions that ...
... paper, paint, and biological tissue are opaque because the ... and seemingly random ways. A new experiment conducted by ... Chemistry Higher Educational Institution (ESPCI) has shown that it,s ... objects hidden behind them, provided you know enough about ...
... IN, MARCH 8, 2010 The Society for ... Dietetic Association (ADA) and American Society for Nutrition ... the American Dietetic Association, American Society for Nutrition, ... Programs for Community-Residing Older Adults," focusing on access ...
Cached Biology News:Environmental engineers receive top science paper award for investigative work 2Environmental engineers receive top science paper award for investigative work 3Nutrition services for older adults at home and in communities 2
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
Biology Products: